financetom
Business
financetom
/
Business
/
Australia's Star Entertainment agrees to take-control offer from Bally's, AFR reports
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Australia's Star Entertainment agrees to take-control offer from Bally's, AFR reports
Apr 6, 2025 6:54 PM

April 7 (Reuters) - Australia's Star Entertainment

has agreed to a refinancing deal, which would see U.S.

peer Bally's take control of the embattled casino

operator, the Australian Financial Review (AFR) reported on

Monday.

Under the deal, Bally's will invest about A$250 million

($149.8 million) while Star's largest shareholder, billionaire

Bruce Mathieson would provide more than A$50 million, the AFR

said, citing three sources with knowledge of the matter.

($1 = 1.6694 Australian dollars)

(Reporting by Aaditya Govind Rao in Bengaluru)

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Berkshire Hathaway cuts stake in China's BYD to below 5%
Berkshire Hathaway cuts stake in China's BYD to below 5%
Jul 22, 2024
NEW YORK, July 22 (Reuters) - Warren Buffett's Berkshire Hathaway ( BRK/A ) reduced its stake in BYD to below 5%, in what could be the final time Berkshire discloses stock sales in China's largest producer of electric vehicles. Berkshire lowered its stake in BYD's issued H-shares to 4.94% from 5.06% on July 16, according to a Monday filing with...
Atossa Therapeutics Completes Enrollment for 80-Milligram Cohort in Study of Potential Breast Cancer Treatment
Atossa Therapeutics Completes Enrollment for 80-Milligram Cohort in Study of Potential Breast Cancer Treatment
Jul 22, 2024
10:10 AM EDT, 07/22/2024 (MT Newswires) -- Atossa Therapeutics ( ATOS ) said Monday that it has completed patient enrollment for the 80-milligram pharmacokinetic run-in cohort of the phase 2 trial of (Z)-endoxifen and exemestane plus goserelin as a treatment for pre-menopausal women with breast cancer. The company said the trial is specifically for grade 1 or 2 estrogen receptor...
TC BioPharm Doses Sixth Person in TCB-008 Trial for Acute Myeloid Leukemia Treatment
TC BioPharm Doses Sixth Person in TCB-008 Trial for Acute Myeloid Leukemia Treatment
Jul 22, 2024
10:12 AM EDT, 07/22/2024 (MT Newswires) -- TC BioPharm ( TCBP ) said Monday it dosed the sixth patient in a trial of TCB-008, a potential treatment for acute myeloid leukemia. The patient got a higher dose after an amendment approved by the UK's Medicines and Healthcare products Regulatory Agency in February, the company said. Five people treated in a...
Accenture to Buy Camelot Management Consultants
Accenture to Buy Camelot Management Consultants
Jul 22, 2024
10:09 AM EDT, 07/22/2024 (MT Newswires) -- Accenture ( ACN ) said Monday it has agreed to buy Camelot Management Consultants, a SAP-focused consulting firm based in Germany. Financial terms weren't disclosed. Camelot's strengths are in areas like supply chain, data and analytics, Accenture ( ACN ) said, adding Camelot has offices in the US, United Arab Emirates, India, Poland,...
Copyright 2023-2026 - www.financetom.com All Rights Reserved